title: The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir.
abstract: BACKGROUND
  Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this study is to examine the impact of pill count on real-world adherence rates in patients treated with SOF + SIM with and without RBV.
  
  
  METHODS
  This retrospective study assessed composite adherence to SOF and SIM over 12 weeks of treatment for two cohorts of hepatitis C patients: one initiating SOF + SIM therapy, and the other initiating SOF + SIM + RBV therapy. Analyses were conducted using MarketScan(®) and Optum US commercial pharmacy claims and enrollment data. Adherence was adjusted by treatment regimen, age, sex, co-pay, presence/absence of cirrhosis, treatment history, and Charlson Comorbidity Index.
  
  
  RESULTS
  There was a significant difference in composite unadjusted and adjusted adherence rates for SOF and SIM for the SOF + SIM vs SOF + SIM + RBV cohorts based on MarketScan data (unadjusted, 92.6% and 89.7%, respectively; P=0.0423; adjusted, 92.2% and 88.7%, respectively; P=0.0176), but not based on Optum data (unadjusted, 94.8% and 95.6%, respectively; P=0.5618; adjusted, 94.8% and 95.1%, respectively; P=0.8589). In the MarketScan and Optum databases, there were no statistical differences in unadjusted and adjusted adherence rates for SOF. Unadjusted and adjusted adherence rates for SIM were mixed, as they were for composite adherence.
  
  
  CONCLUSIONS
  The impact of the addition of RBV to SOF + SIM therapy was mixed. The impact of RBV on SOF adherence was not significant in either database.
authors.affiliation: Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA.
authors.forename: David R
authors.initials: DR
authors.lastname: Walker
authors.affiliation: Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA.
authors.forename: Timothy R
authors.initials: TR
authors.lastname: Juday
authors.affiliation: Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA.
authors.forename: Shivaji R
authors.initials: SR
authors.lastname: Manthena
authors.affiliation: Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA.
authors.forename: Yonghua
authors.initials: Y
authors.lastname: Jing
authors.affiliation: Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA.
authors.forename: Vipan
authors.initials: V
authors.lastname: Sood
keywords: adherence; direct acting antiviral; hepatitis C; ribavirin; simeprevir; sofosbuvir